Sandy T. Liu, MD

Sandy T. Liu, MD

Medical Oncology


Dr. Sandy Liu is a board-certified physician in oncology. She completed her oncology fellowship at UCLA and Internal Medicine residency at Cedars-Sinai Medical Center. She earned her medical degree from George Washington University in Washington D.C. and her bachelors of science in biology at University of Southern California.

Dr. Liu practices general oncology and specializes in genitourinary (GU) cancers which include cancers of the kidney, prostate, bladder, testis, and urethra. She is the sponsoring physician for UCLA VHL Comprehensive Clinical Care Center, which includes a team of VHL specialists working together to provide coordinated care to ensure VHL patients receive access to services and adhere to surveillance guidelines.

Dr. Liu is passionate about advancing the field of cancer treatment and is involved in clinical trials, with research interests in immunotherapy and drug development. She is committed to providing high-quality, personal care to patients and their families.

Dr. Liu is on staff at Ronald Reagan UCLA Santa Monica Medical Center UCLA Hospital and Providence Tarzana Medical Center.

In her free time, she enjoys attending plays and concerts, reading and traveling. She is fluent in English and Mandarin Chinese. She looks forward to providing excellent care to each and every one of her patients.

Additional Practice Locations:
Santa Monica - Cancer Care
2020 Santa Monica Boulevard
Suite 580
Santa Monica, California 90404



Patient Stories

From a Stage III colon cancer diagnosis to a cure, in a year




Medical Board Certifications

Hematology, American Board of Internal Medicine, 2018
Medical Oncology, American Board of Internal Medicine, 2017
Internal Medicine, American Board of Internal Medicine, 2014


UCLA School of Medicine, 2017


Cedars-Sinai Medical Center, 2014


George Washington University School of Medicine, MD, 2011

Hospital Affiliations

Ronald Reagan UCLA Medical Center

UCLA Santa Monica Medical Center



  • Kidney
  • Prostate
  • Bladder
  • Testicular


  1. Liu ST, Hendifar A, Wolin EM. Novel Targets for Future Medical Treatments. Management of Pancreatic Neuroendocrine Tumors. Pisegna, J.R. New York: Springer. 2013
  2. Liu ST, Pham H , Pandol SJ, Ptasznik A.Src as the link between inflammation and cancer. Front Physiol. 2014 Jan 16;4:416.
  3. Hendifar A., Liu ST, Wolin EM, . The role of mTOR inhibitors in neuroendocrine tumors. mTOR Inhibition for Cancer Therapy: Past, Present and Future. Mita, M.M. and Mita, A. New York: Springer. 2014
  4. Wirtschafter E, Walts AE, Liu ST, Marchevsky AM. Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia of the Lung (DIPNECH): Current Best Evidence. Lung. 2015 Oct;193(5):659-67.
  5. Liu ST, Cadaneanu RM, Zhang B, et al. Keratin 13 Is Enriched in Prostate Tubule-Initiating Cells and May Identify Primary Prostate Tumors that Metastasize to the Bone. PLOS One. 2016 Oct 6;11(10).
  6. Sandy T. Liu and Alexandra Drakaki. (2016). Renal Complications. In Manual of Clinical Oncology, Eight Edition. Philadelphia, PA. Lippincott Williams & Wilkins.